TABLE 1.

Clinical characteristics of the first case treated with both delamanid and bedaquiline

	Details	Comments
Country of birth	India
Age	39 years
Sex	Female
Body weight at diagnosis#	65 kg
Case category	Retreatment case
Number of previous anti-TB treatments	4
Drugs administered in previous anti-TB treatments	Kanamycin 750 mg i.m. (12 months) Levofloxacin 1 g, PAS 10 g, cycloserine 750 mg, ethionamide 750 mg, capreomycin 1 g i.m. (14 months) High-dose isoniazid 900 mg, rifabutin 300 mg, clofazimine 200 mg, clarithromycin 1 g, amoxicillin/clavulanate 625 mg, terizidone 1 g three times daily, imipenem 500 mg i.v. three times daily (12 months), linezolid 600 mg then 300 mg
Previous outcome	Cured (twice)
Body mass index at baseline	26.9 kg·m−2
Bacteriology at baseline	Sputum smear positive Culture positive Xpert positive	At Day 18: smear negative Culture taken after 28 days of treatment: ongoing (negative on the 14th day of MGIT culture)
Radiology	Bilateral upper zones fibrocavitary lesions
Drug resistances	Resistant to 12 drugs: Isoniazid, rifampicin, kanamycin, amikacin, capreomycin, moxifloxacin, ofloxacin, ethionamide, PAS, linezolid, high-dose isoniazid, high-dose moxifloxacin Susceptible to: clofazimine
Last treatment regimen	Delamanid, bedaquiline, clofazimine (200 mg), terizidone (1 g) and meropenem 1 g three times daily plus amoxicillin/clavulanate 1 g/200 mg three times daily i.v., all started on February 25, 2016	Bedaquiline stopped on March 7, 2016, restarted March 12, 2016

TB: tuberculosis; PAS: para-aminosalicylic acid; i.m.: intramuscular; i.v.: intravenous; MGIT: mycobacteria growth indicator tube. ^#: August 31, 2015.